Five-year data from Ethicon study of bariatric surgery and diabetes
A study funded by Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon released 5-year data from the Stampede study showing the long-term benefits of bariatric surgery on the symptoms of diabetes.
Stampede enrolled patients with body mass indices of 30 or greater who also had uncontrolled Type II diabetes, comparing gastric bypass or sleeve gastrectomy plus intensive medical therapy with intensive medical therapy alone.
Patients who had surgery showed superior glycemic control and weight reduction, and needed fewer hypertension and hyperlipidemia drugs. Gastric bypass showed some advantages over sleeve gastrectomy in maintaining greateer weight loss and higher rates of diabetes remission, and requiting less medication.
“Stampede’s 5-year results definitively demonstrate the long-term benefit of bariatric surgery with intensive medical therapy over medical management alone in treating obese patients with type 2 diabetes,” Dr. Elliott Fegelman, therapeutic area expert for metabolics at Johnson & Johnson Innovations, said in prepared remarks. “We can now say with certainty that bariatric surgery is a more effective treatment for these patients, completely eliminating the need for diabetes medications in some patients and a marked reduction in need for drug treatment in others. Based on the study results we can move forward identifying the right procedure for each patient, based on that patient’s unique factors.” Read more